Sunzen Biotech Berhad Management
Management criteria checks 3/4
Sunzen Biotech Berhad's CEO is Yek Teo, appointed in Jun 2020, has a tenure of 4.5 years. total yearly compensation is MYR320.94K, comprised of 84.1% salary and 15.9% bonuses, including company stock and options. directly owns 15.24% of the company’s shares, worth MYR37.92M. The average tenure of the management team and the board of directors is 3 years and 4.3 years respectively.
Key information
Yek Teo
Chief executive officer
RM 320.9k
Total compensation
| CEO salary percentage | 84.1% |
| CEO tenure | 4.5yrs |
| CEO ownership | 15.2% |
| Management average tenure | 3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Sunzen Biotech Berhad's (KLSE:SUNZEN) CEO Looks Due For A Compensation Raise
Dec 12
Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations
Nov 07Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit
Oct 15Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher
Aug 06If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity
May 25Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking
May 24Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price
Apr 22Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You
Nov 16Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?
Mar 26Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?
Dec 10
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | RM 321k | RM 270k | RM 6m |
| Dec 31 2023 | n/a | n/a | RM 7m |
| Sep 30 2023 | n/a | n/a | RM 5m |
| Jun 30 2023 | n/a | n/a | RM 4m |
| Mar 31 2023 | n/a | n/a | RM 4m |
| Dec 31 2022 | RM 214k | RM 175k | RM 4m |
| Sep 30 2022 | n/a | n/a | RM 3m |
| Jun 30 2022 | n/a | n/a | RM 2m |
| Mar 31 2022 | n/a | n/a | RM 2m |
| Dec 31 2021 | RM 148k | RM 120k | RM 680k |
| Sep 30 2021 | n/a | n/a | -RM 9m |
| Jun 30 2021 | n/a | n/a | -RM 9m |
| Mar 31 2021 | n/a | n/a | -RM 11m |
| Dec 31 2020 | RM 74k | RM 65k | -RM 13m |
Compensation vs Market: Yek's total compensation ($USD71.24K) is below average for companies of similar size in the MY market ($USD108.84K).
Compensation vs Earnings: Yek's compensation has increased by more than 20% in the past year.
CEO
Yek Teo (40 yo)
4.5yrs
Tenure
RM 320,938
Compensation
Mr. Yek Ming Teo serves as Executive Director at Sunzen Biotech Berhad since June 16, 2020 and served as its Group Managing Director cum Group Chief Executive Officer since June 16, 2020 until February 25,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | RM 114.52k | 0.53% MYR 1.3m | |
| Group MD & Executive Director | 4.5yrs | RM 320.94k | 15.24% MYR 37.9m | |
| Chief Financial Officer | no data | no data | no data | |
| Sales & Marketing Director | no data | no data | no data | |
| Company Secretary | 10.1yrs | no data | no data | |
| Joint Company Secretary | 1.1yrs | no data | no data |
3.0yrs
Average Tenure
47.5yo
Average Age
Experienced Management: SUNZEN's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 4.3yrs | RM 114.52k | 0.53% MYR 1.3m | |
| Group MD & Executive Director | 4.5yrs | RM 320.94k | 15.24% MYR 37.9m | |
| Non Independent Non-Executive Director | 4.3yrs | RM 96.80k | no data | |
| Independent Non-Executive Director | 10.4yrs | RM 43.80k | no data | |
| Independent & Non-Executive Director | 1.8yrs | RM 39.06k | 0.011% MYR 26.6k | |
| Senior Independent & Non Executive Director | less than a year | RM 35.40k | no data |
4.3yrs
Average Tenure
49yo
Average Age
Experienced Board: SUNZEN's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:40 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sunzen Biotech Berhad is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|